8-K: Cardio Diagnostics Unveils Strategic Vision & Clinical Progress

Cardio Diagnostics Holdings, Inc. is holding an investor conference call to discuss corporate updates, recent clinical data, reimbursement progress, and strategic priorities for its precision cardiovascular medicine platform.

Summary

• Cardio Diagnostics Holdings, Inc. (CDIO) is hosting an investor conference call on February 19, 2026, at 3 p.m. Central Standard Time.
• The call will cover corporate updates, recent clinical data, reimbursement progress, and strategic initiatives and long-term objectives.
• The company focuses on precision cardiovascular medicine, leveraging epigenetics and artificial intelligence (AI) for the prevention and early detection of cardiovascular disease.
• It has developed Epi+Gen CHD, a blood test assessing the three-year risk of a coronary heart disease event, and PrecisionCHD, a blood test detecting obstructive and non-obstructive coronary heart disease.
• The total addressable market (TAM) for Epi+Gen CHD is estimated at over $125 billion (146 million eligible Americans), and for PrecisionCHD, over $51 billion (60 million eligible Americans), based on an $854 final CMS payment rate.
• An internal CLIA Lab was recently launched, reducing initial lab Cost of Goods Sold (COGS) by approximately 30% and increasing testing capacity.
• Major reimbursement milestones include CPT PLA codes 0439U and 0440U, both with an $854 final CMS payment rate.
• The company is pursuing U.S. commercial targets through employers/unions, providers/health systems, and channel partners.
• Global expansion is underway with an announced partnership in India with Aimil Ltd and Dr. Lal PathLabs.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive update, showcasing significant progress in product development, market penetration, and reimbursement, with a clear strategic vision for growth in a large and critical healthcare segment.

Positives

• Developed the first and only commercial solutions leveraging epigenetics and AI for cardiovascular disease prevention and early detection.
• Over $176 billion total addressable market (TAM) across Epi+Gen CHD and PrecisionCHD.
• Commercially available, clinically validated tests with growing adoption.
• Strong and growing pipeline supported by ongoing studies and new product development.
• Robust intellectual property portfolio with multiple granted US and international patents.
• Diversified US and international commercialization strategy, including a partnership in India.
• Meaningful reimbursement milestones achieved, including $854 final CMS payment rates for both tests.
• Experienced leadership team with expertise across diagnostics, AI, and commercialization.
• Internal CLIA Lab recently launched, reducing initial lab COGS by approximately 30% and increasing testing capacity.
• Epi+Gen CHD offers up to $42,000 in cost savings per quality-adjusted life year (QALY).
• PrecisionCHD could save approximately $113 million in the first year if used as the primary initial CHD assessment for one million lives.
• PrecisionCHD shows superior sensitivity compared to traditional methods (2.4x more sensitive for women, 1.7x for men for Epi+Gen CHD; 1.3x for women, 1.4x for men for PrecisionCHD).
• Preliminary data presented at AHA and ACC conferences demonstrate the utility of PrecisionCHD in detecting Ischemia with No Obstructive Coronary Arteries (INOCA) and predicting mortality in Acute Coronary Syndrome (ACS) patients.

Risks

• Ability to successfully execute growth strategy.
• Changes in laws or regulations.
• Economic conditions.
• Dependence on management.
• Dilution to stockholders.
• Lack of capital.
• Effects of rapid growth upon the Company and management's ability to respond.
• Newly developing technologies.
• Company's ability to compete.
• Regulatory matters.
• Protection of technology.
• Ability to obtain future financing.
• Actual results and events may differ significantly from results and events discussed in forward-looking statements.

Future Outlook

The company aims to scale operations, expand its product pipeline through ongoing studies and new product development, achieve Medicare coverage, establish out-of-network billing, engage commercial payers for pilot programs, and pursue further partner-led international expansion in Asia, the Middle East, and Africa.

Management Comments

• Management will discuss corporate updates, recent developments, ongoing strategic priorities, recent clinical data, reimbursement progress, and strategic initiatives and long-term objectives during the investor call.

Industry Context

StockSavvy.ai notes that Cardio Diagnostics is positioning itself at the forefront of precision medicine, a growing trend in healthcare, by integrating epigenetics and AI. This approach addresses the significant global burden and rising costs of cardiovascular disease, a leading cause of death, by offering more personalized and precise prevention and early detection tools. The focus on non-invasive, radiation-free tests like Epi+Gen CHD and PrecisionCHD aligns with increasing patient demand for accessible and convenient diagnostic solutions, potentially disrupting traditional diagnostic pathways.

Comparison to Industry Standards

• Epi+Gen CHD is 2.4x more sensitive for women and 1.7x more sensitive for men compared to the average sensitivity of the Framingham Risk Score and the ASCVD Pooled Cohort Equation, which are common risk calculators used by clinicians.
• PrecisionCHD is 1.3x more sensitive for women and 1.4x more sensitive for men compared to the average sensitivity of a stress ECG for initial CHD assessment.
• PrecisionCHD and PrecisionCHD + imaging can better predict mortality in Acute Coronary Syndrome (ACS) patients than imaging alone, with AUCs of 0.701 and 0.729 respectively, compared to Duke Jeopardy Scores (an angiographic measure) at 0.647.
• The company claims to have developed the first and only commercial solutions leveraging epigenetics and AI for cardiovascular disease prevention and early detection, setting a new standard in the field.

Stakeholder Impact

• Shareholders: Potential for increased value through market expansion, successful reimbursement, and clinical adoption of proprietary tests.
• Patients: Improved access to personalized, precise, and non-invasive tools for cardiovascular disease prevention and early detection, potentially leading to better health outcomes and reduced costs.
• Healthcare Providers/Systems: Access to advanced diagnostic tools that can enhance risk stratification, diagnostic accuracy, and treatment guidance, potentially reducing hospitalizations and improving patient management.
• Payers/Employers: Potential for significant cost savings in cardiovascular disease management through early detection and prevention, leading to reduced direct medical costs and lost productivity.
• Employees: Growth and expansion could lead to increased opportunities and stability within the company.

Next Steps

• Continue Medicare coverage process (final required step for Medicare).
• Establish out-of-network billing capability (expected in Q2 2026).
• Engage commercial payers for pilot programs.
• Expand evidence on the utility of the PrecisionCHD test to detect both obstructive and non-obstructive coronary heart disease (INOCA).
• Continue multi-modal, multi-time scale study demonstrating the ability of PrecisionCHD to detect coronary heart disease earlier than imaging and predict mortality risk.
• Use PrecisionCHD to inform treatment for inflammatory coronary heart disease with LODOCO and monitor treatment effectiveness (partnership with Agepha Pharma).
• Explore other partner-led international expansion opportunities in Asia, Middle East, and Africa.

Key Dates

Recommendation

The filing highlights Cardio Diagnostics' unique position with proprietary, clinically validated epigenetic and AI-powered tests addressing a massive and growing cardiovascular disease market. Significant progress in reimbursement, the launch of an internal lab for cost efficiency, and strategic global partnerships demonstrate strong execution and future growth potential. The compelling clinical data and cost-saving benefits of their tests, coupled with an experienced management team, suggest a strong upside for investors.

Keywords

Cardio Diagnostics, CDIO, epigenetics, artificial intelligence, AI, cardiovascular disease, precision medicine, diagnostics, heart health, coronary heart disease, CHD, INOCA, ACS, medical technology, healthcare, SEC filing, investor presentation, reimbursement, clinical data